China: Healthcare

Subscribe

Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.

China Releases 2025 Typical Cases On Patent Reexamination And Invalidation

China's national intellectual property administration (CNIPA) has released ten typical cases from 2025 involving patent reexamination and invalidation. These cases were selected because they are highly relevant...

AC

AFD China

China Boosts Medical Innovation For Public Health

China will accelerate the development of core medical technologies and innovative drugs targeting common and complex diseases, including cardiovascular conditions...

China Healthcare

AC

AFD China

Beijing Intellectual Property Court Releases 2025 Annual Case List

On April 21, 2026, the Beijing Intellectual Property Court published its annual case list for 2025. The release includes ten main cases (available in both Chinese and English) and nine nominated cases.

AC

AFD China

China Compliance Update: Life Sciences — Spring 2026

Chinese regulators intensified anti-corruption enforcement in the life sciences sector during 2026, with particular emphasis on medical insurance fraud, investigator-initiated studies, and patient programs.

China Healthcare

AP

Arnold & Porter

China On The Move: Key Takeaways From The 2025 NRDL Negotiations And Adjustment

China Healthcare

GT

Greenberg Traurig, LLP

2025年度广告合规洞察：监管新规下的合规之道

China Media & IT

FP

Fangda Partners

开启直播电商合规新纪元 |《直播电商监督管理办法》重点解读（下）

China Media & IT

FP

Fangda Partners

A Legal Commentary On The Latest Implementing Regulations Of The PRC Drug Administration Law

China Healthcare

FP

Fangda Partners

China Newsletter | Q3 2025/Issue No. 65

GT

Greenberg Traurig, LLP

Navigating China's Health Transformation: Opportunities And Challenges For Multinationals

China Healthcare

AC

Ankura Consulting Group LLC

Ten Minefields: A Guide To Avoiding Pitfalls In Applying For Human Genetic Resources Projects In China

China Healthcare

HK

Han Kun Law Offices

China Released Draft Medical Device Law For Comments

China Healthcare

HK

Han Kun Law Offices

Understanding China's Pharmaceutical Patent Linkage System: Framework And Case Overview (Part 1)

CT

Chang Tsi & Partners

シーメンス・ヘルスケア、中国国際輸入博覧会で「現地革新」の成果を披露

K

Kangxin

최고인민법원은 지식재산권과 관련된 악의적 소송에 대응한 대표적 판례 발표

K

Kangxin

China’s Pharma Innovators Pursue A Range Of Deal Structures To Support Global Expansion

China Healthcare

AO

A&O Shearman

PRC Financial Regulation Annual Report (2026) FinTech

Worldwide Technology

FP

Fangda Partners

PRC Financial Regulation Annual Report (2026) General

FP

Fangda Partners

海关法领域2025年政策回顾与2026年展望：出口管制、关税及企业应对

China International

AB

AnJie Broad Law Firm

Discussion On The Patent Eligibility Of Smart Healthcare

The rapid advancement of artificial intelligence technology is reshaping the technical boundaries within the medical and healthcare techniques.

K

Kangxin

China Life Sciences Compliance Update: Insurance Fraud Enforcement Campaign And New Ethical Code For HCPs

Chinese authorities have launched a special "Hundred-Day Campaign" to target misconduct relating to China's state-run medical insurance program and issued a new Ethical Code for Healthcare Professionals...

China Healthcare

AP

Arnold & Porter

China Life Sciences Compliance Update: Kickback And Third-Party Case Study

A recent criminal judgment published by the Gao'an People's Court in Jiangxi province (江西省高安市人民法院) in June 2025 has drawn public attention to Jiangxi Baishen Pharmaceutical Co.

China Healthcare

AP

Arnold & Porter

Redefining Beauty: Navigating Chinas Medical Aesthetics Upheaval

The medical aesthetics industry in China is experiencing a transformative phase, establishing itself as a leading global market segment...

China Healthcare

KP

KPMG

Llinks Corporate Compliance & Legal Alert

China Commercial

LO

Llinks Law Offices

医药健康企业融资谈判过程中需要创始人注意的两三事（上篇）

China Healthcare

JT

Beijing Jincheng Tongda & Neal Law Firm

Understanding The EU's International Procurement Instrument

China Government

CM

Crowell & Moring LLP

汉坤 • 观点 | 《药品管理法实施条例》（修订草案）重点快评

China Healthcare

HK

Han Kun Law Offices

汉坤 • 观点 | 中国药品年度报告制度简析

China Healthcare

HK

Han Kun Law Offices

汉坤 • 观点 | 简评新版《医疗器械临床试验质量管理规范（GCP）》

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Interpretation Of The "Detailed Rules For The Supervision Of Internet Diagnosis And Treatment (Trial)"

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Research On Urban Customized Commercial Medical Insurance

China Insurance

HK

Han Kun Law Offices

汉坤 • 观点 | 医药BD项目如何友好"分手"？

China Healthcare

HK

Han Kun Law Offices

How Digital Therapeutics (DTx) Products Are Regulated In China?

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Interpretation Of The "Detailed Rules For The Supervision Of Internet Diagnosis And Treatment (Trial)"

Since the General Office of the State Council issued the "Opinions on Promoting the Development of "Internet + Medical Health" on April 25...

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Research On Urban Customized Commercial Medical Insurance

In order to promote the construction of a healthy China, our country has continuously strengthened the top-level design of the universal medical security system.

China Insurance

HK

Han Kun Law Offices

汉坤 • 观点 | 医药BD项目如何友好"分手"？

医药BD(business development，商务拓展)项目通常指通过授权许可、投资、并购、合作开发/商业化等方式进行产品和技术的商业机会拓展。全球新冠疫情已逾三年，

China Healthcare

HK

Han Kun Law Offices

How Digital Therapeutics (DTx) Products Are Regulated In China?

This article discusses the regulation of DTx products in China, the question of registration, and best practices for collecting and processing data through DTx products.

China Healthcare

HK

Han Kun Law Offices

2024 Data Analytics: China Life Sciences NewCo & Licensing Terms

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Implementation And Regulation Of DCT (Decentralized Clinical Trials) In China

The concept of "patient-centered" has become the core guiding ideology of current drug development. "Patient-centered" drug development refers to the process...

China Healthcare

HK

Han Kun Law Offices

汉坤 • 观点 | LDT试点新规解读

近年来，我国不断探索对LDT的监管。随着一系列新规的出台，有众多优秀的跨国及本土公司均参与到该领域的研究中...

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | The Spring Of Traditional Chinese Medicine? From The "Special Provisions On The Registration And Administration Of Traditional Chinese Medicines", The Characteristic Marketing Evaluation System Of Traditional Chinese Medicine

In recent years, our country has been vigorously supporting the inheritance, innovation and development of traditional Chinese medicine. In 2019...

China Healthcare

HK

Han Kun Law Offices

药企出海新热点：管线分拆"SON"模式的实践解读

近期，医药行业正掀起一股"管线分拆项目"（"Spin off-NewCo"，或称"SON"模式）的热潮。短短两个月，笔者即接手了近十起管线分拆项目。

China Healthcare

HK

Han Kun Law Offices

Han Kun Opinion | Breaking News: 10 Questions And Answers On Pharmaceutical Anti-Corruption In 2023

China Healthcare

HK

Han Kun Law Offices

Han Kun Opinion | CAR-T/NK Regulatory Decisions — Interpreting The "Guidelines For Somatic Cell Clinical Research (Trial)"

China Healthcare

HK

Han Kun Law Offices

汉坤 • 观点 | 从药械产品全生命周期视角解读License-in/out许可交易项目合作条款要点

China Healthcare

HK

Han Kun Law Offices

汉坤 • 观点 | 企业或需自设伦理委员会：《科技伦理审查办法（试行）》正式出台

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Interpret The New Regulations For The Inspection Of Drug Clinical Trial Institutions In The Post-"722 Storm" Era

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | 2023 Life Sciences Regulatory Compliance Annual Summary

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Quick Review Of The New Regulations: Interpret The Latest Questions And Answers Of The Ministry Of Science And Technology

China Healthcare

HK

Han Kun Law Offices

Han Kun • Quick Comment | Is The Transmission Of Cross-border Genomic Data Between China And The United States Blocked? Biden Data Executive Order Quick Review

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Analysis Of Key Points Of License-In/out Contract Disputes In The Life Sciences Industry (1): Joint Steering Committee, Reasonable Commercial Efforts, Confidentiality Obligations

China Healthcare

HK

Han Kun Law Offices

Hankun • Quick Comment | The Regulations On Human Genetic Resources Management Are Revised Again

China Healthcare

HK

Han Kun Law Offices

2022-2023 China Medical Device License-In/Out Project Core Clause Data Analysis

China Healthcare

HK

Han Kun Law Offices

61款创新医疗器械获批：2023年度中国医疗器械注册工作报告亮点解读

China Healthcare

HK

Han Kun Law Offices

Overview: 2022-2023 China Drug & Medical Device Annual Report

China Healthcare

HK

Han Kun Law Offices

Top 10 Traps To Avoid: Navigating China's HGR Applications

China Healthcare

HK

Han Kun Law Offices

观点 | 生命科学行业License-In/Out合同争议要点分析（二）：适应症变更、监管要求变更、合同变更或解除

China Healthcare

HK

Han Kun Law Offices

See more

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More